The Three Criteria for PCOS Diagnosis and the Insulin-Androgen Feedback Loop

In May 2003, inside a conference room in Rotterdam, Netherlands, 27 endocrinologists and gynecologists from the European Society of Human Reproduction and Embryology and the American Society for Reproductive Medicine sat down to solve a definition problem. For the preceding 13 years, doctors had been diagnosing polycystic ovary syndrome (PCOS) using a rigid 1990 checklist that required both irregular periods and high androgens, missing millions of women who presented differently. By the end of that meeting, the panel had drafted a new framework—the Rotterdam criteria—that expanded the diagnosis, fundamentally changing how the medical system identifies the most common endocrine disorder in women of reproductive age.[1]

The Rotterdam consensus established that a patient only needs to meet two out of three specific clinical signs to receive a PCOS diagnosis. The first criterion is oligo-ovulation or anovulation, meaning menstrual cycles are irregular, infrequent, or absent entirely. The second is clinical or biochemical signs of hyperandrogenism, which manifests as elevated testosterone levels on a blood test, or physical signs like hirsutism (excess facial or body hair) and severe acne.[1][2]

The third criterion is the presence of polycystic ovaries on an ultrasound. Specifically, the 2003 guidelines defined this as having 12 or more follicles measuring 2 to 9 millimeters in diameter in at least one ovary, or an increased ovarian volume of more than 10 milliliters. These are not true cysts in the traditional sense, but rather immature ovarian follicles that halted their development prematurely due to hormonal imbalances.[1][2]

By requiring only two of the three criteria, the Rotterdam framework created four distinct phenotypes of PCOS. A woman might have irregular periods and high androgens but completely normal-looking ovaries on an ultrasound. Another might have polycystic ovaries and high androgens but regular menstrual cycles. According to the Endocrine Society's clinical practice guideline, "We recommend using the Rotterdam criteria for diagnosing PCOS in adult women," because it captures the full spectrum of how the syndrome presents in clinics.[3][8]

The name "polycystic ovary syndrome" is increasingly viewed by specialists as a misnomer that focuses too heavily on reproductive anatomy. The American College of Obstetricians and Gynecologists (ACOG) notes that the syndrome is fundamentally a systemic metabolic and endocrine disorder. At the core of this systemic disruption is a mechanism that affects up to 80% of women with the condition: the insulin-androgen feedback loop.[2][9]

Insulin is the hormone responsible for moving glucose from the bloodstream into cells to be used for energy. In many women with PCOS, the body's cells become resistant to insulin's signal. To compensate and keep blood sugar levels stable, the pancreas pumps out significantly more insulin, creating a state of chronic hyperinsulinemia.[4][6]

This excess insulin travels throughout the body and binds to receptors on the theca cells within the ovaries. Theca cells are responsible for producing androgens, the precursors to estrogen. When stimulated by high levels of insulin, these cells go into overdrive, producing excess testosterone and other androgens at rates far above normal physiological needs.[4][5]

The resulting hyperandrogenism is what halts the development of ovarian follicles, leading to the "polycystic" appearance on an ultrasound and preventing the release of an egg. But the biochemical cascade does not stop at the ovaries. The excess androgens enter the bloodstream and actively worsen the body's metabolic state, creating a self-perpetuating cycle.[5][9]

Elevated testosterone alters how the body stores fat, directing it toward the visceral area around the abdomen. Visceral fat is highly metabolically active and secretes inflammatory cytokines that directly impair insulin signaling in muscle and liver tissues. As insulin resistance worsens, the pancreas secretes even more insulin, which in turn commands the ovaries to produce even more testosterone.[5][6]

The loop is further accelerated by the liver. High insulin levels suppress the liver's production of sex hormone-binding globulin (SHBG). SHBG acts as a sponge in the bloodstream, binding to testosterone and rendering it inactive. With less SHBG available, the amount of free, active testosterone circulating in the blood spikes, intensifying symptoms like hair loss and acne while driving further insulin resistance.[4][8]

Understanding this feedback loop changes how patients and doctors approach treatment. If PCOS is viewed solely as a menstrual irregularity, the default treatment is often an oral contraceptive pill to force a regular bleed. While contraceptives effectively lower androgens and protect the uterine lining, they do not resolve the underlying hyperinsulinemia driving the systemic loop.[2][7]

Breaking the cycle requires targeting the metabolic root. The 2023 International Evidence-based Guideline from the American Society for Reproductive Medicine emphasizes lifestyle modifications—specifically nutrition and movement that improve cellular insulin sensitivity—as the first-line intervention. When muscle cells become more responsive to insulin through resistance training or aerobic exercise, the pancreas can lower its insulin output.[3][8]

Medical interventions also target this pathway directly. Metformin, an insulin-sensitizing medication, is frequently prescribed to lower circulating insulin levels, which subsequently reduces ovarian androgen production. By addressing the metabolic driver rather than just the reproductive symptoms, patients can effectively disrupt the feedback loop, restoring both hormonal balance and long-term metabolic health.[7][8]